Integrin alpha 6 is upregulated and drives hepatocellular carcinoma progression through integrin α6β4 complex

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Integrin alpha6 (ITGA6) forms heterodimers with integrin beta1 (ITGB1) or integrin beta4 (ITGB4).
• The specific role of ITGA6 in hepatocellular carcinoma (HCC) progression remains unclear.

Purpose of the Study:

• To investigate the role of ITGA6 in HCC progression.
• To determine the interaction partners of ITGA6 in HCC.
• To evaluate ITGA6 as a potential therapeutic target for HCC.

Main Methods:

• RNA sequencing, RT-qPCR, Western blotting, and immunofluorescence staining were used to assess ITGA6 expression.
• In vitro and in vivo experiments using ITGA6 knockdown and anti-ITGA6 antibodies were performed.
• Immunoprecipitation assays were conducted to identify ITGA6 interaction partners.

Main Results:

• ITGA6 expression was significantly upregulated in HCC tissues compared to adjacent non-tumor tissues.
• ITGA6 knockdown inhibited HCC cell proliferation, migration, anchorage-independent growth, and xenograft tumor growth.
• ITGA6 interacted with ITGB4, not ITGB1, and positively regulated ITGB4 expression.
• High co-expression of ITGA6 and ITGB4 correlated with worse patient survival.

Conclusions:

• ITGA6 is upregulated in HCC and promotes tumor malignancy.
• The integrin alpha6beta4 (ITGA6/ITGB4) complex plays a critical role in HCC progression.
• Integrin alpha6beta4 represents a potential therapeutic target for HCC treatment.